Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.60 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | GAA | P10253 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | GLA | P06280 | 4/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8514081 | 0.92 | AKT1 (0.56) | AKT1CYP1A1MAPTPBRM1KDM4E | |
| SCHEMBL10237816 | 0.85 | AKT1 (0.54) | AKT1CYP1A1MAPTPBRM1KDM4E | |
| SCHEMBL2784350 | 0.84 | AKT1 (0.72) | AKT1CYP1A1MAPTKDM4EALDH1A1 | |
| SCHEMBL2784941 | 0.84 | AKT1 (0.72) | AKT1CYP1A1MAPTKDM4EALDH1A1 | |
| SCHEMBL2783197 | 0.84 | AKT1 (0.72) | AKT1CYP1A1MAPTKDM4EALDH1A1 | |
| SCHEMBL873832 | 0.79 | AKT1 (0.49) | AKT1CYP1A1MAPTPBRM1KDM4E | |
| SCHEMBL8512880 | 0.78 | AKT1 (0.47) | AKT1CYP1A1MAPTPBRM1KDM4E | |
| SCHEMBL8511469 | 0.76 | AKT1 (0.46) | AKT1CYP1A1MAPTPBRM1KDM4E | |
| SCHEMBL1821389 | 0.76 | MAPT (0.71) | MAPTPBRM1KDM4EALDH1A1GAA | |
| SCHEMBL15441431 | 0.75 | AKT1 (1.00) | AKT1CYP1A1MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-04-05 | — | — | US | disclosed |
| WO-2012040641-A2 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | AKT1 1528/4885CYP1A1 3366/4885MAPT 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.